LENZ Therapeutics, Inc.

NASDAQ:LENZ

Biotechnology

Healthcare
$3.21 -6.62%

-$0.42 today

Market cap
$100.86M
Beta
1.47
P/E (TTM)
-1.7
EPS (TTM)
-$3.48
52W Low $5.85High $50.40

Volume 0.62M

Average 0.89M

LENZ Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

LENZ Therapeutics, Inc.NASDAQ: LENZ

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow dips below year-ago levels

Q1 FY2026 financing cash flow of $14K fell 68.2% year over year, behind the +439.0% change in trailing-twelve-month financing cash flow. Sequentially, it fell 100.0% from the prior quarter. Over 3 fiscal years it compounded at +530.7% a year.

Context

  • Financing cash flow amounted to 784.5% of revenue in FY2025.
  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -68.2% toward the trailing-twelve-month pace of +439.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14K-100.0% QoQ
Last fiscal yearDec 2025
$149.75M-24.8% YoY
LTMMar 2026
$149.72M+439.0% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-68.2%——
1 year-24.8%——
3-year CAGR+530.7%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
149.75M USD
Year-over-year change
-24.8%
4-year CAGR
-22.6%

Financing Cash Flow vs competitors

How LENZ compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +439.0% is the 3rd highest of 11, against a peer median of +27.8%.
  • Financing cash flow amounts to 713.3% of revenue for LENZ, versus a peer median of 91.9%.
LENZ Competitors
Financing Cash Flow for LENZ and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TYRATyra Biosciences, Inc.LTM Mar 2026$166.3M USD+4048.1%+134.0%—
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$164.27M USD-32.1%-55.5%78.7%
LENZLENZ Therapeutics, Inc.LTM Mar 2026$149.72M USD+439.0%+530.7%713.3%
PRMEPrime Medicine, Inc.LTM Mar 2026$145.91M USD+227.5%-5.8%3616.9%
SVRASavara Inc.LTM Mar 2026$135.29M USD+12.9%+1065.7%—
SPRYARS Pharmaceuticals, Inc.LTM Mar 2026$104.03M USD+42.8%-18.1%105.1%
RZLTRezolute, Inc.LTM Mar 2026$103.17M USD+48.5%-10.4%—
NBTXNanobiotix S.A.FY2025€37.42M EUR+828.6%—126.2%
ABUSArbutus Biopharma CorporationLTM Mar 2026$14.56M USD-52.0%-43.6%7.6%
GERNGeron CorporationLTM Mar 2026$4.44M USD-97.6%-70.4%2.3%
GHRSGH Research PLCLTM Mar 2026$2.23M USD-101.6%——
Peer median (excluding LENZ) —+27.8%-14.3%91.9%

Competitors are the stored peer set for LENZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(70.76M)(101.05M)(69.97M)(49.77M)(82.13M)
Depreciation & Amortization734K8.35M15K58K(3.12M)
Deferred Income Tax00000
Stock-Based Compensation001.34M6.37M12.55M
Change in Working Capital(2.5M)(7.21M)9.41M(13.09M)3.25M
Accounts Receivables0000(329K)
Inventory0000(4.28M)
Accounts Payables1.83M194K856K(4.28M)(90K)
Other Working Capital(4.32M)(7.4M)8.55M(8.81M)7.95M
Other Non-Cash Items19.67M11.93M(1.18M)(2.95M)279K
Operating Cash Flow(52.85M)(87.98M)(60.38M)(59.39M)(69.17M)
Capital Expenditures(5.74M)(6.59M)(30K)(468K)(827K)
Acquisitions (Net)00000
Purchases of Investments0(405.52M)(52.09M)(241.91M)(280.8M)
Sales of Investments0170.25M22.5M87.9M205.96M
Other Investing Activities00000
Investing Cash Flow(5.74M)(241.86M)(29.62M)(154.48M)(75.67M)
Debt Repayment00000
Common Stock Issued417.16M676K203K79.51M149.75M
Common Stock Repurchased0(79K)000
Dividends Paid00000
Other Financing Activities306K0(2.48M)119.49M0
Financing Cash Flow417.47M597K80.7M199M149.75M
Effect of Forex Changes(1.72M)0000
Net Change in Cash357.16M(329.25M)(9.3M)(14.87M)4.91M
Free Cash Flow(58.59M)(94.57M)(60.41M)(59.86M)(70M)

LENZ Therapeutics, Inc.

NASDAQ:LENZ

Intrinsic Alpha fair value

Locked

Current Price

$3.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.